Cookies on this site

The Role of PYY in Pancreatic Islet Physiology and Surgical Control of Diabetes

Guida C., Stephen S., Guitton R., Ramracheya RD.

Bariatric surgery in obese individuals leads to rapid and lasting remission of type 2 diabetes (T2D). This phenomenon occurs independently of weight loss possibly via a combination of factors. The incretin hormone GLP-1 has so far been recognised as a critical factor. However, recent data have indicated that elevation in another gut hormone, peptide tyrosine tyrosine (PYY), may drive the beneficial effects of surgery. Here we discuss recent findings on PYY-mediated control of glucose homeostasis and its role in diabetes, in the context of what is known for GLP-1. Identification of factors that increase the expression of PYY following bariatric surgery and elucidation of its role in diabetes reversal may have clinical relevance as a nonsurgical therapy for T2D. Bariatric surgeries are weight loss interventions, which result in a spectacular reversal of type 2 diabetes (T2D) and associated metabolic benefits in man. The gut hormone GLP-1 has been considered as the ‘holy grail’ of this phenomenon and the involvement of other incretins, namely PYY, which is also expressed in the pancreatic islets, has been largely overlooked and under-rated. PYY is a key factor in diabetes remission following bariatric surgery in rats. Moreover, elevated PYY levels in patients after surgery are associated with improved glucose responses. PYY modulates insulin and glucagon secretion in isolated rat and human islets via unidentified mechanisms and it is critical for the preservation of islet morphology and secretory function. Like GLP-1, PPY has been associated with proliferative and protective effects on pancreatic β cells. The impact of PYY in mediating the antidiabetic effects of gastric bypass surgery implies that a pharmacological agent enhancing PYY release or its action could provide an effective and nonsurgical therapy for T2D.